GNMSF News and Press, Genmab A/S Dkk From 06/27/19

The FDA approves Johnson & Johnson ( JNJ -0.5% ) unit Janssen Biotech's Darzalex (daratumumab), combined with Celgene's Revlimid (lenalidomide) and dexamethasone, for the first-line treatment of multiple myeloma (MM) patients who are ineligible for autologous stem cell transplantatio...

BlackRock ( BLK -1.1% ) has decreased its stake in Genmab A/S ( OTCPK:GNMSF +0.5% ) to less than 5%. More news on: BlackRock, Inc., Genmab A/S, Financial stocks news, Healthcare stocks news, Read more ...

Genmab A/S (GNMSF) Q1 2019 Earnings Conference Call May 8, 2019, 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, CEO and President David Eatwell - EVP and CFO Conference Call Participants Wimal Kapadia - Sanford C. Bernstein & Co. Thomas Bowers - Danske...

The following slide deck was published by Genmab A/S in conjunction with their 2019 Q1 earnings Read more ...

Genmab A/S ( OTCPK:GNMSF ) announces that Janssen Pharmaceutica NV has submitted a Type II variation application to the EMA. More news on: Genmab A/S, Genmab A/S, Healthcare stocks news, Read more ...

The following slide deck was published by Genmab A/S in conjunction with this Read more ...

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Genmab ( GNMSF ) and their par...

Genmab A/S ( OTCPK:GNMSF ) announces that a Phase 3 clinical trial, MAIA , evaluating licensee Janssen Biotech's (NYSE: JNJ ) DARZALEX (daratumumab), combined with Celgene's (NASDAQ: CELG ) REVLIMID (lenalidomide) and dexamethasone (DRd), compared to REVLIMID and dexamethasone alone (Rd) ...

Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...

Fresenius Medical Care ( FMS +1.5% )( OTCPK:FMCQF )( OTCPK:FSMEM ) assumed with Hold rating and €82 price target at Jefferies. More news on: Fresenius Medical Care AG & Co. KGAA, Fresenius Medical Care AG & Co KGaA, Fresenius Medical Care Holdings, Healthcare stocks news, ...